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Abstract. Purpose: Intracavitary radioimmunotherapy
(RIT) offers an effective adjuvant therapeutic approach
in patients with malignant gliomas. Since differentiation
between recurrence and reactive changes following RIT
has a critical impact on patient management, the aim of
this study was to analyse the value of serial O-(2-[
18F]
fluoroethyl)-L-tyrosine (FET) PET scans in monitoring the
effects of this locoregional treatment.
Methods: Following conventional therapy, 24 glioma
patients (5 WHO III, 19 WHO IV) underwent one to
five RIT cycles with either
131I-labelled (n=19) or
188Re-
labelled (n=5) anti-tenascin antibodies. Patients were
monitored with serial FET PET scans (2–12 scans). For
semiquantitative evaluation, maximal tumoural uptake
(TUmax) was evaluated and the ratio to background (BG)
was calculated. Results of PET were correlated with
histopathological findings (n=9) and long-term clinical
follow-up for up to 87 months.
Results: In seven tumour-free patients, PET revealed
slightly increasing but homogeneous FET uptake sur-
rounding the resection cavity with a peak up to 18 months
following RIT (TUmax/BG 2.07±0.25) but stable or
decreasing values during further follow-up (last follow-
up: TUmax/BG 1.63±0.22). Seventeen patients developed
regrowth of residual tumour/tumour recurrence showing
additional nodular FET uptake (TUmax/BG 2.79±0.53). A
threshold value of 2.4 (TUmax/BG) allowed best differen-
tiation between recurrence and reactive changes (sensitiv-
ity 82%, specificity 100%).
Conclusion: FET PET is a sensitive tool for monitoring the
effects of locoregional RIT. Homogeneous, slightly in-
creasing FET uptake around the tumour cavity with a peak
up to 18 months after RIT, followed by stable or
decreasing uptake, points to benign, therapy-related
changes. In contrast, nodular uptake is a reliable indicator
of recurrence.
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Introduction
The life expectancy of patients with high-grade gliomas, in
particular glioblastoma multiforme, is still very poor.
Standard treatment including surgery, radiation therapy
and, if suitable, systemic chemotherapy results in median
survival times ranging between 1 year for glioblastoma and
about 3 years for anaplastic astrocytoma [1, 2]. Standard
treatment is not able to control tumour progression for a
longer period since in most cases microscopic tumour cell
clusters located in the peritumoural brain tissue are left and
become the starting point for (usually) early tumour
recurrence [3, 4]: complete surgical resection or eradication
by subsequent conventional radiation therapy is usually
impossible. To overcome these limitations, more specific
approaches for brain tumour treatment have been intro-
duced, such as additional targeted radiotherapy, e.g. in
form of a locoregional radioimmunotherapy (RIT) [5–9].
The infusion of radiolabelled monoclonal antibodies
directly into the postsurgical resection cavity after surgery
has enabled the delivery of high radiation doses to the
affected area without harming the surrounding normal
brain tissue or distant organs.
Treatment efficacy can be evaluated by different neuro-
imaging modalities. Conventional magnetic resonance
imaging (MRI) and computed tomography (CT) assess
morphological parameters such as changes in tumour size,
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and alterations in blood-brain barrier properties are not
always related to tumour regrowth; rather, they can also
represent non-specific inflammatory treatment effects and
radiation or tumour necrosis, especially after locoregional
administration of high-dose radiation [10–12]. Functional
imaging methods have been proposed as an alternative for
monitoring treatment and are claimed to be more specific
than structural imaging methods.
Positron emission tomography (PET) using radiola-
belled amino acid analogues, particularly [methyl-
11C]-L-
methionine (MET) and, in recent years, O-(2-[
18F]
fluoroethyl)-L-tyrosine (FET), has been employed in
numerous metabolic studies of malignant brain tumours
[13–21]. Since amino acid uptake has been shown to be
increased relative to normal brain tissue in most low- and
high-grade tumours, it has gained an important role in the
diagnostic work-up of brain tumours [21–24]. PET using
MET or FET has also been shown to differentiate reliably
between tumour recurrence and post-therapeutic benign
lesions after standard treatment modalities like surgery,
external radiation therapy or chemotherapy [15,16, 20, 25–
28]. In a recent study, FET PET was evaluated for the first
time in a novel locoregional therapeutic approach, for the
purpose of monitoring the effects of convection-enhanced
delivery of paclitaxel in patients with recurrent glioblas-
toma. Preliminary data in a small patient group suggested
that FET PET seems to fulfil the clinical requirement for a
method that is sensitive enough to assess therapeutic effects
early and to distinguish between harmless post-therapeutic
changes and tumour regrowth after this aggressive
locoregional approach [29].
The aim of the present study was to evaluate the
diagnostic value of FET PET in another locoregional
approach, namely in monitoring the therapeutic effects of
locoregional RIT following intracavitary administration of
131I- or
188Re-labelled monoclonal anti-tenascin antibodies
(TN-mAb).
Materials and methods
Patients
Twenty-four patients (9 females, 15 males) with a mean age of 49±14
years and histopathologically proven tenascin expression of malig-
nant gliomas (5 anaplastic astrocytomas, 19 glioblastomas) were
included in the study. All patients had undergone primary surgery on
the tumour or re-operation of tumour recurrence with implantation of
an Ommaya reservoir into the resection cavity. Primary surgery had
been followed in 23 of the 24 patients by external radiation therapy
and in six patients by additional systemic chemotherapy.
In 7 of the 24 patients, small residual tumours with an average
diameter of less than 1 cm had to be left because of their location in
high-risk and functionally important areas. In 17 patients no obvious
tumour was seen on baseline MRI examinations. Patients underwent
one to five cycles of intracavitary RIT with
131I-labelled (n=19) or
188Re-labelled(n=5)murineTN-mAb(BC4,whichisdirectedagainst
theEGF-likerepeatsofhumanTN)at6-to8-weekintervals(maximal
cumulativeactivity5,740MBqfor
131Iand470MBqfor
188Re).In20
patients, serial FET PET and MRI scans were performed preceding
every RITcycle and at 3-month intervals after the end of RITin order
to detect tumour recurrence and to monitor the therapeutic effects. In
the remaining four patients, follow-up with serial FET PETscans was
not started until 10, 12, 17 and 33 months after the end of RIT.
Altogether, a total of 119 PET scans were performed.
PET studies
FET PET scans were obtained with a Siemens ECAT EXACT HR+
scanner. To obtain standardised metabolic conditions, patients fasted
for a minimum of 6 h before performing the PET scan. The scanner
acquires 63 contiguous transaxial planes, simultaneously covering
15.5 cm of axial field of view. After a 15-min transmission scan
(
68Ge sources), 180 MBq [
18F]FETwas injected intravenously. Since
FETaccumulates and reaches a peakin malignant gliomas within 15–
20 min after injection and only slowly decreases afterwards [14], a
static PETstudy from 20 to 50 min post injection (three added frames
of 10 min each, 128×128 matrix, 3D acquisition) was acquired to
obtain adequate count rate statistics. Images were reconstructed by
filtered backprojection using a Hann filter with a cutoff frequency of
0.5 Nyquist and corrected for scatter and attenuation. For semiquan-
titative evaluation, data were transferred to a HERMES work station
(Hermes Medical Solutions, Sweden) and the slice with the highest
FET uptake around the former resection cavity was evaluated. For
this slice, maximal uptake (maximal counts within the tumour:
TUmax) was determined and the ratio to the background (BG) was
calculated. For background information, the mean uptake within a
70% isocontour threshold ROI mirrored to the opposite non-tumour-
bearing hemisphere was determined.
Statistical analysis
The diagnostic performance in differentiating between recurrence
and tumour-free status was assessed by receiver operating charac-
teristic (ROC) analyses [30, 31]. For this purpose, data of serial PET
scans were separately categorised into true- and false-positive and
true- and false-negative findings using clinical follow-up or the
results of histopathology as the gold standard. Then sensitivity (SN)
and specificity (SP) pairs as a function of the respective decision
thresholds were plotted as ROC curves to describe the inherent
discrimination capacity of the diagnostic system and to define the
optimal threshold for decision making. The threshold was considered
optimal when the sum of paired values for SN and SP reached a
maximum in two evaluations: the analysis of all performed scans
(n=119) and the analysis of only that scan of each patient which
presented with the highest uptake value during the entire follow-up
period.
In addition, SN and SPvalues are given for a visualanalysis using
nodular versus non-nodular FETuptake as the criterion to distinguish
between patients with tumour recurrence and tumour-free patients.
The duration of progression-free survival after the first RITcycle
was computed according to the Kaplan-Meier method using the
SPSS for Windows (SPSS, Version 13.0, Chicago, IL) statistics
package. Two groups were compared, those with maximal individual
TUmax/BG ratios above ≥2.4 and those with ratios below <2.4, which
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recurrent tumour and reactive post-therapeutic changes. Statistical
differences between the two curves were tested using log rank and
Breslow tests.
Results
Our clinical experience with RIT has been reported
previously. We observed substantially prolonged survival
times for patients who received RIT (n=37: a larger number
than in this study) compared with a similarly treated group
without additional RIT [5]. Therefore, readers are referred
to this previous article for information on the clinical
findings associated with this form of therapy; here we shall
focus on the role of FET PET during follow-up only.
During the study period, 17 of the 24 patients ultimately
presented with tumour progression while seven were
considered tumour free. For the latter group, Table 1
summarises patient characteristics, number and time points
of RIT cycles and cumulative activity, number of serial
PET scans with FET uptake ratios at baseline and last
follow-up, and patient survival after initial surgery. The
tumour-free status was documented by biopsy in two
patients (these patients presented with contrast enhance-
ment on MRI which was highly suspicious for recurrence)
and by stable clinical follow-up for between 23 and 87
months after initial surgery in the other five. Six of these
seven patients demonstrated slightly increasing homoge-
neous FETuptake surrounding the resection cavity without
any signs of additional nodular uptake; this uptake
presented with a peak (baseline TUmax/BG 1.78±0.30,
peak TUmax/BG 2.07±0.25, mean±SD) up to 18 months
after RIT, followed by stable or decreasing values (last
follow-up TUmax/BG 1.63±0.22; representative example in
Fig. 1). One of these six patients unfortunately decided to
discontinue the follow-up with FET PET 4 months after
RIT. However, this patient was clinically followed and
showed a stable course over 27 months after RIT and 35
months after initial surgery. In one of the seven patients
with slightly increased stable and homogeneous FET
uptake, RIT had been completed about 3 years prior to
the beginning of FET PET monitoring; therefore the post-
therapeutic phase of increasing FET uptake and its peak
were probably missed. The peak values of TUmax/BG
observed in tumour-free patients corresponded to the
threshold value of 2.4 for TUmax/BG ratio as assessed by
ROC analyses which allowed best differentiation between
post-therapeutic reactive changes and tumour recurrence.
In this small patient group, the extent and changes of FET
uptake over time following RIT seemed to be independent
of the delivered radiation dose since the peak TUmax/BG
ratio reached similar levels in all patients. Furthermore, the
time point of the peak uptake, which ranged between 2 and
18 months, also showed no obvious relation with the dose
administered.
Among the 17 of 24 patients who ultimately presented
with tumour progression, ten experienced tumour recur-
rence and seven, regrowth of residual tumour. These
diagnoses were histopathologically proven by stereotactic
biopsy in five patients and by re-operation in three patients.
In the remaining nine patients, suspected tumour regrowth
or recurrence was assumed because of concordantly
increasing contrast enhancement on MRI and clinical
deterioration. Table 2 summarises the characteristics and
results of patients with progressive disease. The ten
patients without obvious tumour at baseline initially
presented with normal ratios (TUmax/BG 1.64±0.26) but
showed focally increasing FET uptake values, resulting in
pathological ratios during follow-up (TUmax/BG 2.67±
0.43). A representative example is shown in Fig. 2.I n
seven patients with known residual tumour on the baseline
scan, further FET PET investigations demonstrated patho-
logical ratios which were stable or increased over time
(baseline TUmax/BG 2.49±0.42; last follow-up TUmax/BG
3.04±0.49). Six of these seven patients showed patholog-
Table 1. Patient and tumour characteristics and therapeutic details of tumour-free patients
Age
(yrs)
Sex WHO Surgery RIT
cycles
Cum. activity
(MBq)/nuclide
RIT No. of PET
scans
TUmax/BG:
baseline
TUmax/
BG: peak
TUmax/BG: last
follow-up
Survival (mo.)
post surgery
Serial FET PET monitoring started after the end of RIT
36 f III 05/99 2 2,460/131 I 10/99–
11/99
9 – 2.4 (02/01) 1.5 (01/05) 77 (l.c.)
39 m III 10/98 5 5,740/131 I 05/99–
01/00
8 – 2.3 (09/01) 1.5 (10/05) 85 (l.c.)
37 f IV 03/00 1 1,270/131 I 11/00 12 – 2.1 (04/02) 1.5 (02/05) 66 (l.c.)
54 f IV 08/98 3 3,490/131 I 04/99–
08/99
5 – peak
missed
1.6 (05/05) 87 (l.c.)
Serial FET PET monitoring during and after RIT
27 f IV 08/01 1 1,280/131 I 03/02 3 2.0 (02/02) 2.2 (04/02) 2.0 (06/02) 35 (l.c.)
22 f IV 01/04 3 3,560/131 I 10/04–
02/05
6 1.4 (09/04) 2.1 (04/05) 1.8 (09/05) 21 (l.c.)
40 f IV 11/03 1 380/188 Re 05/04 7 1.4 (04/04) 1.7 (03/05) 1.4 (09/05) 23 (l.c.)
l.c. last contact
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interestingly, in one of the seven patients (with anaplastic
astrocytoma WHO grade III), MRI was rated as normal
owing to the lack of contrast enhancement, whereas the
concomitant PET scan showed pathological focal FET
uptake ventral of the cavity, clearly indicating recurrence.
This was proven by stereotactic biopsy. This patient
underwent re-operation of this area, but unfortunately
developed another tumour manifestation distant from the
primary location that showed contrast enhancement on
MRI as well (Fig. 3).
In total, 119 PET scans were performed, 34 in the
presence of recurrent tumours and 85 while the patient had
a tumour-free status. ROC analyses based on two
approaches—(a) including all performed PET scans
(Fig. 4a) and (b) considering only the PET scan with the
highest individual uptake in each patient during follow-up
(n=24) (Fig. 4b)—demonstrated the highest discrimination
capacity between patients with tumour recurrence and
tumour-free patients at a threshold value of 2.4 for the
TUmax/BG ratio.
Comparison of patients with ratios below and above this
threshold using Kaplan-Meier curves for progression-free
survival (Fig. 5) demonstrated that survival times were
significantly longer (p<0.05) in patients presenting with
values below this threshold.
Visual analysis using a nodular versus a non-nodular
uptake pattern as the criterion to distinguish between
tumour recurrence and tumour-free status led to correct
detection of recurrence in 32 of 34 scans (sensitivity 94%).
In 80 of 85 scans performed in a tumour-free status, no
additional nodular uptake pattern was present (specificity
94%). In five scans, uptake appeared somewhat focally
accentuated owing to circumscribed folding of the cavity
wall, and thus mimicked nodular uptake. Restricting visual
analysis only to the one scan per patient presenting with the
highest FET uptake resulted in correct detection of tumour
recurrence in 16 of 17 patients (sensitivity 94%) and of a
tumour-free status in five of seven (specificity 71%). In two
of seven tumour-free patients, FET uptake that appeared
nodular was misleading for reasons mentioned above.
Discussion
Recent studies on locoregional RIT have demonstrated
that local administration of radiolabelled monoclonal
antibodies may significantly prolong survival times in
patients with malignant gliomas [5–9]. The high locally
achieved radiation dose, however, may cause inflamma-
tory infiltrates and radiation necrosis more frequently than
do standard treatment modalities, rendering differential
diagnosis between benign reactive post-therapeutic effects
and tumour recurrence more difficult. In particular,
abnormal contrast enhancement in necrotic tissue often
mimics tumour recurrence and, therefore, neither MRI nor
CT allows reliable distinction between tumour and
reactive changes in contrast-enhancing lesions [10–12].
Due to the poor prognosis of patients with glioma,
however, knowledge of whether RIT has been successful
or not is required so that a decision can be made to re-
operate or to change to alternative aggressive treatment
modalities when necessary.
So far, to our knowledge only one study has reported on
results of functional imaging following RIT of glioma.
Using PET with FDG as the metabolic marker, Marriott et
al. [32] reported in a limited number of ten patients that a
metabolic rim of FDG was observed around the tumour
09/00 07/02 02/01 11/03 01/05
2.1 1.8 2.4 1.6 1.5
Fig. 1. Serial MRI and FET PETscans of a 36-year-old woman after
surgery for an anaplastic astrocytoma WHO III and following two
RIT cycles (10/99 and 11/99 with 2,460 MBq
131I-TN-mAb). The
patient was clinically tumour free at follow-up for up to 77 months
after surgery. Slight linear contrast enhancement surrounding the
small tumour cavity in the right central area is observed on MRI. On
FET PET there is slightly increasing homogeneous FET uptake
surrounding the cavity (which in this particular case mimics a more
focal appearance owing to the small lesion size in combination with
the limited resolution of the PET scanner), peaking 15 months after
RIT (02/01) and decreasing during further follow-up. The respective
TUmax/BG ratios are given below the PET images
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131I-labelled
monoclonal antibodies. Based on their findings they
suggested that the development of such a rim may be
dose dependent but independent of malignant disease.
Histologically, the metabolic rim was associated with an
inflammatory infiltrate consisting of a relatively increased
number of macrophages and fibroblasts. Furthermore,
malignant recurrence was suggested in the event of
development of new nodularity in the non-malignant
FDG-accumulating rim.
To our knowledge, there have been no previous reports
of experience with PETand amino acid tracers as metabolic
markers in the special setting of locoregional RIT. A recent
study that monitored a limited number of patients with FET
PETafter another locoregional treatment of glioma, namely
convection-enhanced delivery of paclitaxel, suggested that
FET PET may be more reliable than MRI in differentiating
reactive post-therapeutic changes in stable disease from
tumour progression [29]. These results strongly encourage
the evaluation of FET PET for monitoring of other forms of
locoregional glioma therapy.
This is the first study to investigate the use of an amino
acid tracer to monitor the effects of locoregional admin-
istration of radiolabelled monoclonal antibodies. Twenty-
four patients with malignant gliomas were followed up
with serial FET PETscans during and/or after intracavitary
RIT. Similar to the results reported by Marriott et al. [32],
in all cases, even those considered tumour free, PET
demonstrated slight homogeneous FETuptake surrounding
the resection cavity, which was considered to be a
consequence of therapy. However, the results of in vitro
and animal studies on the uptake of FET in soft tissue
infection [33] or cerebral radiation injury [34] suggest that
FET uptake is probably to be explained by a breakdown in
the blood-brain barrier rather than by active uptake in
macrophages or inflammatory infiltrates, as in the case of
FDG. This is supported by the following four observations:
Breakdown of the blood-brain barrier following RIT was
documented in all patients by a linear contrast-enhancing
rim surrounding the resection cavity on MRI scans. Kaim
et al. demonstrated that FET uptake was not increased in
activated white blood cells of experimental soft tissue
infection [33]. In rats, comparison of tracer accumulation in
Table 2. Patient and tumour characteristics and therapeutic details of patients with tumour recurrence or regrowth of residual tumour during
follow-up
Age
(yrs)
Sex WHO Surgery RIT
cycles
Cum. activity
(MBq)/nuclide
RIT No. of PET
scans
TUmax/BG:
baseline
TUmax/BG: last
follow-up
Survival (mo.) post
surgery
Patients without obvious tumour at baseline followed by tumour recurrence
40 m III 10/00 3 4,510/131 I 05/02–
10/02
6 1.5 (12/01) 2.5 (03/03) 36 (†)
53 m IV 08/01 1 1,690/131 I 03/02 2 1.7 (01/02) 3.1 (04/02) 19 (†)
46 f IV 11/01 3 4,550/131 I 07/02–
01/03
6 1.5 (07/02) 2.0 (09/03) 26 (†)
70 m IV 04/03 2 3,020/131 I 02/04–
06/04
4 1.8 (02/04) 2.7 (09/04) 22 (†)
69 m IV 05/04 2 470/188 Re 07/04–
10/04
4 2.1 (07/04) 3.3 (03/05) 13 (l.c.)
55 m IV 07/02 3 3,060/131 I 11/03–
03/04
5 2.0 (09/03) 2.1 (09/04) 34 (†)
61 m IV 12/02 1 1,770/131 I 10/03 2 1.6 (08/03) 2.8 (12/03) 17 (l.c.)
56 m IV 04/03 1 1,850/131 I 10/03 7 1.6 (10/03) 2.5 (02/05) 24 (l.c.)
37 f III 04/01 3 4,130/131 I 01/05–
05/05
5 1.2 (12/04) 2.4 (07/05) 54 (l.c.)
39 f IV 03/04 2 1,420/131 I 07/04–
10/04
6 1.6 (07/04) 2.8 (07/05) 19 (l.c.)
Patients with small residual tumour at baseline followed by tumour progression
30 m III 02/01 1 1,870/131 I 07/02 4 2.6 (07/02) 4.0 (12/02) 25 (†)
61 m IV 04/00 3 4,250/131 I 09/01–
12/01
3 3.3 (09/01) 3.6 (12/01) 25 (†)
60 m IV 02/01 2 2,670/131 I 12/01–
01/02
3 2.5 (12/01) 2.6 (03/02) 28 (†)
59 m IV 05/03 1 380/188 Re 03/04 3 2.1 (03/04) 2.9 (07/04) 24 (l.c.)
68 m IV 10/02 1 370/188 Re 05/04 2 2.5 (05/04) 3.1 (06/04) 21 (l.c.)
50 m IV 10/03 1 1,110/131 I 01/04 2 2.1 (01/04) 2.2 (03/04) 12 (l.c.)
68 m IV 08/02 2 4,090/131 I 02/05–
07/05
5 2.3 (11/04) 2.9 (09/05) 38 (l.c.)
† death, l.c. last contact
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Fig. 3. Serial MRI and FET PET scans of a 30-year-old man after
surgery and radiation therapy of an anaplastic astrocytoma, WHO
III, located in the right parietal lobe before and after 1 RIT cycle
(07/02 with 1870 MBq 131I-TN-mAk): a At baseline and 3 months
after therapy, slightly increased homogeneous FET uptake at the
cavity borders with additional nodular FET uptake ventral of the
cavity indicating recurrence. MRI shows no suspicious contrast
enhancement. b After reoperation development of another tumour
manifestation developed distant the primary location with focal FET
uptake and contrast enhancement on MRI as well. The TUmax/BG
ratios are given below the PET images
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Threshold value SN SP
2.0 94% 29%
2.1 94% 43%
2.2 88% 71%
2.3 82%8 6 %
2.4 82% 100%
2.5 71%1 0 0%
n=2 4
(single scan/pt.)
B Fig. 4. ROC curves illustrating
the diagnostic performance of
FET PET when varying the
decision thresholds. Analyses
were performed twice: for all
available PET scans (n=119,
including 85 scans performed
while patients had a tumour-free
status and 34 scans in patients
with recurrent tumours) (a) and
for only that scan presenting
with the highest individual up-
take (n=24) (b). The sensitivity
and specificity pairs for the
threshold values between 2.0
and 2.5 are given in the boxes
2.1 1.9 2.1 3.3
07/04 09/04 12/04 03/05
Fig. 2. Serial MRI and FET PET
images of a 69-year-old man
after surgery and radiation ther-
apy of a glioblastoma located in
the left occipital lobe during
and after two RIT cycles (07/04
and 10/04 with 470 MBq
188Re-
TN-mAb). Slightly increased
homogeneous FET uptake is
evident surrounding the tumour
cavity (07/04–12/04). Develop-
ment of tumour recurrence
lateral to the resection cavity is
indicated by additional nodular
FET uptake as shown in the last
scan (03/05). The respective
TUmax/BG ratios are given
below the PET images
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cells and radiation injury demonstrated that slight FET
uptake was most likely due to a disruption of the blood-
brain barrier and not additional trapping by macrophages.
Uptake in radiation injury has generally been reported to be
lower than uptake in tumours, suggesting that FET may be
superior to FDG for distinguishing radiation necrosis from
tumour recurrence [34].
In general, the homogeneous FET uptake around the
resection cavity after RIT was somewhat higher than the
unspecific uptake observed in a larger patient group after
surgery and conventional external radiation therapy [20].
For these standard treatment modalities, the preliminary
threshold value for best differentiation between post-
therapeutic effects and tumour recurrence has been
considered to be 2.0 for the TUmax/BG ratio, whereas in
the present study following RIT the threshold value was
determined to be 2.4. The somewhat higher unspecific FET
uptake after RIT may be explained by a more severe
breakdown of the blood-brain barrier, probably induced by
the higher local radiation dose. However, based on the
limited experience so far, we were not able to document a
relationship between extent and time course of FET uptake
with the dose administered.
In addition to these general considerations regarding the
rim uptake, the time course of FET uptake in relation to the
RIT cycles also has to be taken into account. In the seven
patients without clinical signs of tumour recurrence, PET
demonstrated slightly increasing values initially, with a
peak at up to 18 months after RIT, and stable or even
decreasing values during further follow-up. In these
patients, FET uptake was homogeneous and the TUmax/
BG ratio reached the threshold value of 2.4 in only one
patient and then in only one (peak) of nine serial scans. In
contrast, in the 17 patients presenting with tumour
progression during follow-up, PET showed a more focally
configured FET uptake in addition to the rim uptake.
Semiquantitative evaluation of the slice with the highest
uptake showed either stably increased values (in patients
with residual tumour) or increasing values, starting from
normal ratios and progressing to pathological ratios (in
patients who developed recurrence).
Using the threshold value of 2.4 (as determined by ROC
analyses) and regardless of the uptake pattern, FET PET
was able to distinguish with high discriminatory power
between tumour progression during or after RIT and
therapy-induced benign changes: in 21/24 patients there
was accurate assessment in all serial PET scans, while in
the remaining three patients there was false negative
assessment, with TUmax/BG ratios of 2.0, 2.1 and 2.2
respectively. However, in all three cases the nodular
configuration of FET uptake led to the correct diagnosis.
Even in one patient without focal contrast enhancement on
MRI, PET showed focally increased FET uptake clearly
indicating tumour regrowth, which was later proven by
biopsy. Incidentally, this case supports the hypothesis that
tumoural uptake independent of blood-brain barrier dis-
ruption is mainly mediated by active transport via the
transport system L [35–37]. Visual assessment based solely
on the FET uptake pattern seemed to provide slightly more
sensitive results than those obtained by the ratio method,
but at a lower specificity. Both the TUmax/BG ratio and the
configuration of FET uptake should be taken into account
in order to differentiate optimally between recurrence and
benign post-therapeutic effects. If findings are then still
considered equivocal, a shorter time interval between
follow-up scans (e.g. 6 weeks) offers another option to
achieve reliable diagnostic assessment as early as possible.
Even though it was not the aim of this study to assess the
predictive value of FET PET for clinical outcome, FET
uptake values following RIT could have been used to
compare Kaplan-Meier-overall survival curves of patients
with ratios below and above the suggested threshold value
(TUmax/BG<2.4). This approach, however, was not
followed in our study owing to the heterogeneous patient
group (patients with and without residual tumour at
baseline, various intervals between initial surgery and
radioimmunotherapy, various starting points of FET PET
monitoring). Instead, a Kaplan-Meier analysis for progres-
sion-free survival following RIT was performed, showing
significantly longer progression-free survival in patients in
whom the maximal individual uptake was below the
suggested threshold value, compared to those presenting
with values above this threshold.
One possible limitation of the present study was the lack
of histological confirmation in 15/24 patients, and
especially in five of the seven patients who were
considered tumour free. Histopathological confirmation
would have been ethically hard to justify in these patients,
but its lack gives rise to the question of possible false
negative findings. Nevertheless, the unsuspicious long-
term clinical follow-up in the patients in question and the
fact that the study population consisted only of patients
with high-grade gliomas, and in particular glioblastomas
(19/24 patients), strongly support the PET results.
Another possible limitation is that in four of the 24
patients, follow-up with serial FET PET scans did not start
until at least 10 months after the end of RIT, with the
Fig. 5. Kaplan-Meier curves showing progression-free survival in
patients with ratios below (top) and above (bottom) the suggested
optimal threshold value (TUmax/BG=2.4)
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following RIT might have been missed. However, since in
three of those four patients FET uptake was still increasing
during the initial PET scans, followed by a peak and
subsequent decrease, it is unlikely that crucial information
was missed. Only in one patient in whom RIT had been
completed as long as 33 months prior to the beginning of
FET PET monitoring were the post-therapeutic phase of
increasing FET uptake and its peak probably missed.
Finally, in the present study we abstained from system-
atically correlating FET PETresults with MRI data because
the primary goal was to evaluate the value of serial FET
PET scans for monitoring the effects of intracavitary RIT.
Direct correlations between FET PETand MRI in a similar
series of patients following multimodal systemic and/or
locoregional treatment have been published recently [38],
showing that MRI is insufficient to distinguish between
benign side-effects of therapy and tumour recurrence and
that FET PET is a powerful tool to improve the differential
diagnosis in these patients. Therefore, FET PET might be a
method of choice for monitoring locoregional forms of
treatment, like RIT, which frequently cause treatment-
related inflammatory reactions or tumour necrosis.
Conclusion
This study indicates that FET PET is a sensitive tool for
monitoring the effects of high local radiation doses given
by intracavitary RIT. Homogeneous, slightly increasing
FET uptake around the tumour cavity with a peak up to 18
months after RIT, followed by stable or decreasing FET
uptake, is indicative of benign, therapy-related changes.
These findings are independent of tumour recurrence and
must not be misinterpreted as progressive disease. In
contrast, focally increased FET uptake is an early and
reliable indicator of tumour progression.
Since both radiation necrosis and active tumour growth
can present with clinical deterioration and are often
impossible to distinguish by means of structural brain
imaging, FET PET may be a powerful tool for planning
further patient management. While radiation necrosis may
be treated by steroids or, in extensive cases, by debulking
surgery, recurrent tumour requires change of ineffective
treatment or palliative care only.
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